Details
Structure visualisation
Entry information
| Complex | |
| AACDB_ID: | 1367 |
| PDBID: | 5G5X |
| Chains: | B_A |
| Organism: | Archaeoglobus fulgidus, Lama glama |
| Method: | XRD |
| Resolution (Å): | 2.80 |
| Reference: | 10.1016/j.bbamem.2017.05.006 |
| Antibody | |
| Antibody: | Nb330 Nanobody |
| Antibody mutation: | No |
| INN (Clinical Trial): | |
| Antigen | |
| Antigen: | SITE-2 PROTEASE |
| Antigen mutation: | No |
| Durg Target: | |
Sequence information
Antibody
Chain: B
Mutation: NULL
| >5G5X_B|Chain B|NANOBODY|LAMA GLAMA (9844) QVQLQESGGGLVQPGGSLRLSCAASGSGFNNNAMGWYRQAPGKQRELVAAITSFGSTNYADSVKGRFTISRDNAKNTVYLQMNSLKPEDTAVYYCTAGWGATPRSYWGQGTQVTVSSHHHHHH |
Antigen
Chain: A
Mutation: NULL
| >5G5X_A|Chain A|SITE-2 PROTEASE|ARCHAEOGLOBUS FULGIDUS (2234) MDVMNTEVVTVTPEMTVSEVIDLILKTKHLGFPVVEGERLVGIITLHDIIGVEPEERVGNIMSREVVAVSPNQSAFEAFKIMSEMGIGRLPVVEHGRVVGIVSRSDLMRIKEILEALEVMGWRKRGSSLEWSHPQFEK |
Interaction
1、Solvent accessible surface areas (SASA) were calculated (Naccess V2.1.1) for each residue in antibody and antigen, respectively. The residues with SASA loss in binding of more than 1Å2 were classified as interacting residues.
Interacting residues (ΔSASA based)
| B: ASN30 ASN31 TYR37 ARG45 GLU46 LEU47 THR52 SER53 PHE54 SER56 THR57 ASN58 TYR59 ALA60 ASP61 TRP99 GLY100 ALA101 THR102 ARG104 SER105 A: THR240 GLU241 VAL242 VAL243 THR244 VAL245 THR246 MET249 THR250 SER252 GLU253 ASP256 LEU257 LYS260 THR261 VAL269 GLU270 GLY271 GLU272 ARG273 ARG331 |
2、We defined interacting paratope-epitope residues by a distance cutoff of < 5Å . Two amino acids are considered as interacting residues if they have at least one atom within a distance of 5 Å from any atom.
Interacting residues (Atom distance based)
